Photodynamic therapy as palliative treatment for recurrent squamous cell carcinom of the head and neck region

Christel B. Lajer, Dep. of Otolaryngology head and neck surgery, Rigshospitalet0 个研究点目标入组 50 人开始时间: 2004年12月8日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Patients with recurrent squamous cell carcinoma unsuitable for curative intended surgery or radiotherapy
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•·Age < 18 years
•·Porfyria or other diseases exacerbated by light.
•·Hypersensitivity to temoporfin or to any of the excipients.
•·Known allergy to porphyrins.
•·Tumours known to be eroding into a major blood vessels in or adjacent to the illuminated site.
•·Planned surgery within 30 days after treatment.
•·Coexisting ophthalmic disease likely to require slit lamp examination within 30 days after treatment.
•·Existing therapy with a photosensitizing agent.
•·Patients incapable of understanding patient information and/or are unable to follow precautions against light exposure 30 days post treatment.
•·Diabetes mellitus.
•·Other known malignancies.

发起方

Christel B. Lajer, Dep. of Otolaryngology head and neck surgery, Rigshospitalet